^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
Published date:
03/17/2021
Excerpt:
A 27-year-old man was diagnosed with a stage IIIAcT3N2M0 (7thUICC/AJCC) upper left lung adenocarcinoma harboring EML4-ALK fusion...Five months after SRS, the intracranial oligometastasis showed a complete response based on the RECIST 1.1 criteria...The patient’s overall survival (OS) time is currently 68 months.
DOI:
10.3389/fonc.2021.655856
